Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

CSLR

Complete Solaria Inc.

Oct 22 • 04:00PM ET

2.46

Dollar change +0.09
Percentage change 3.80	%

Technology • Solar • USA • NASD

Peers: SEDG ENPH FSLR RUN SPWR JKS CSIQ MAXN SHLS ARRY

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-2.48	Insider Own	36.02%	Shs Outstand	49.07M	Perf Week	15.49%
Market Cap	156.48M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	-19.66%	Shs Float	40.70M	Perf Month	-12.77%
Income	-110.50M	PEG	-	EPS next Q	-0.10	Inst Own	20.94%	Short Float	2.09%	Perf Quarter	61.84%
Sales	59.85M	P/S	2.61	EPS this Y	84.68%	Inst Trans	-36.90%	Short Ratio	1.38	Perf Half Y	472.09%
Book/sh	-1.46	P/B	-	EPS next Y	60.82%	ROA	-128.08%	Short Interest	0.85M	Perf Year	110.26%
Cash/sh	0.03	P/C	85.04	EPS next 5Y	-	ROE	-2937.39%	52W Range	0.20 - 3.37	Perf YTD	53.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-27.00%	Beta	0.85
Dividend TTM	-	Quick Ratio	0.19	Sales past 5Y	10.60%	Gross Margin	17.24%	52W Low	1130.00%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	0.21	EPS Y/Y TTM	-3591.80%	Oper. Margin	-73.80%	RSI (14)	53.45	Volatility	8.30% 11.35%
Employees	134	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-184.63%	Recom	1.00	Target Price	4.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-70.06%	Payout	-	Rel Volume	1.70	Prev Close	2.37
Sales Surprise	-57.22%	EPS Surprise	-154.55%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	618.35K	Price	2.46
SMA20	-0.29%	SMA50	11.03%	SMA200	77.41%	Trades		Volume	1,028,085	Change	3.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight	$6

Oct-15-24 08:30AM	Complete Solar Appoints Solar Industry Veteran Dan Myers Executive Vice President of New Homes Division (GlobeNewswire)
Sep-24-24 10:47AM	Court Approves Complete Solar Purchase of SunPower Assets (GlobeNewswire) +6.03%
Sep-16-24 08:26AM	Complete Solar is Winning Bidder in SunPower Chapter 11 Proceedings (GlobeNewswire) +18.18%
Sep-09-24 08:30AM	Complete Solar Raises $40.5 Million for SunPower Asset Acquisition (GlobeNewswire)
Aug-14-24 08:30AM	SunPower Seeks to Designate Complete Solar as Stalking Horse in Its Bankruptcy Asset Purchase Agreement (APA) (GlobeNewswire)
08:30AM	Loading…
Aug-12-24 08:30AM	Complete Solaria to Report Second Quarter Financial and Operational Results on August 14, 2024 (GlobeNewswire)
Aug-06-24 08:30AM	Complete Solaria Discusses SunPower Acquisition Opportunity (GlobeNewswire) +10.00%
Aug-05-24 09:49PM	SunPower Announces Stalking Horse Asset Purchase Agreement with Complete Solaria to Sell Blue Raven Solar, New Homes, and its Non-Installing Dealer Network (PR Newswire)
Jul-17-24 08:52AM	Complete Solar Raises $10 Million from Chinese Energy Company (GlobeNewswire) -5.56%
Jul-15-24 08:30AM	Complete Solar Acquires Core Energy (GlobeNewswire) -7.43%
Jul-01-24 10:34AM	XELA Stock Alert: Exela Announces Spinoff of BPA Company (InvestorPlace) +32.14%
10:16AM	Why Is Complete Solaria (CSLR) Stock Up 41% Today? (InvestorPlace)
07:00AM	Complete Solaria Eliminates $67.6 Million of Private Equity Debt (GlobeNewswire)
Jun-17-24 04:05PM	Complete Solaria Raises $10 Million in Convertible Debenture to Pay Off Carlyle Debt (GlobeNewswire)
Jun-13-24 09:00AM	Complete Solaria Appoints Daniel Foley Chief Financial Officer (GlobeNewswire)
08:54AM	Loading…
May-16-24 08:54AM	CSLR Stock Earnings: Complete Solaria Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +10.64%
08:30AM	Complete Solaria Appoints Solar Industry Veteran Aaron Semliatschenko as VP, U.S. Operations (GlobeNewswire)
May-15-24 08:00AM	Complete Solaria Signs Term Sheet to Eliminate Carlyle Debt (GlobeNewswire) +37.74%
May-04-24 10:23AM	Complete Solaria, Inc. (NASDAQ:CSLR) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 03:00PM	Kline Hill Invests in Complete Solaria with Debt-Equity Swap (GlobeNewswire) +11.59%
02:30PM	Complete Solaria to be Self-Funded in Q2 2024 (GlobeNewswire)
Apr-30-24 07:45AM	Complete Solaria to Report Fourth Quarter 2023 and First Quarter 2024 Financial and Operational Results on May 2, 2024 (GlobeNewswire) -15.09%
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:30AM	REPEAT - Complete Solaria Names T.J. Rodgers CEO (GlobeNewswire)
Apr-29-24 12:47PM	Complete Solaria Names T.J. Rodgers CEO (GlobeNewswire) +91.70%
Apr-21-24 03:51PM	Retail Stock Sector and Chairman T.J. Rodgers Invest in Complete Solaria (GlobeNewswire)
Apr-18-24 03:57PM	Apparent CSLR Short Attack Just After Issuing Options (GlobeNewswire)
Apr-11-24 08:14AM	Complete Solaria Update: Operational Progress & PE Debt (GlobeNewswire)
Apr-05-24 06:52AM	CSLR Stock Earnings: Complete Solaria Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.64%
Dec-21-23 08:35AM	Complete Solaria Announces an Equity Investment from Its Chairman (GlobeNewswire) +9.35%
09:00AM	Loading…
Dec-11-23 09:00AM	Complete Solaria Appoints Solar Industry Veteran and Growth Expert Chris Lundell as its New CEO (GlobeNewswire)
Nov-27-23 07:30AM	Complete Solaria Announces Will Anderson to Remain Interim CEO (GlobeNewswire)
Nov-14-23 06:27PM	Complete Solaria Reports Third Quarter 2023 Results (GlobeNewswire) +9.09% -7.94%
Oct-30-23 07:30AM	Complete Solaria to Report Third Quarter 2023 Earnings on November 14, 2023 (GlobeNewswire) +5.56%
Oct-18-23 04:05PM	Complete Solaria Completes Asset Sale, Realigning Portfolio and Accelerating Path to Profitability (GlobeNewswire) -13.29%
Sep-20-23 04:15PM	Maxeon Solar Technologies and Complete Solaria Sign Definitive Agreement for Purchase of Sales Channel Assets and Shingled Solar Panel IP by Maxeon (GlobeNewswire) -5.20%
Aug-22-23 04:10PM	Complete Solaria Reports Second Quarter 2023 Results (GlobeNewswire) -14.67%
Aug-21-23 07:30AM	Complete Solaria Agrees to Terms to Sell Certain North American Solar Panel Assets (GlobeNewswire)
Aug-16-23 03:26PM	Complete Solaria to Host Second Quarter & Business Update Call on August 22, 2023 (GlobeNewswire) -11.20%

Complete Solaria, Inc. engages in the provision of solar services. It offers sales enablement, project management, partner coordination, and customer communication. The company is headquartered in San Ramon, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 17 '24	Sale	2.33	250,000	582,250	2,155,461	Oct 21 05:11 PM
Carlyle Group Inc.	10% Owner	Oct 17 '24	Sale	2.33	250,000	582,250	2,155,461	Oct 21 05:09 PM
Carlyle Group Inc.	10% Owner	Oct 16 '24	Sale	2.20	275,000	603,790	2,405,461	Oct 17 04:30 PM
Carlyle Group Inc.	10% Owner	Oct 15 '24	Sale	2.12	225,000	475,920	2,680,461	Oct 17 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 16 '24	Sale	2.20	275,000	603,790	2,405,461	Oct 17 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 15 '24	Sale	2.12	225,000	475,920	2,680,461	Oct 17 04:30 PM
Carlyle Group Inc.	10% Owner	Oct 14 '24	Sale	2.23	250,000	558,475	2,905,461	Oct 15 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 14 '24	Sale	2.23	250,000	558,475	2,905,461	Oct 15 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 11 '24	Sale	2.27	92,905	211,257	3,155,461	Oct 15 04:30 PM
Carlyle Group Inc.	10% Owner	Oct 11 '24	Sale	2.27	92,905	211,257	3,155,461	Oct 15 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 09 '24	Sale	2.14	924,466	1,981,223	3,643,231	Oct 11 04:35 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 10 '24	Sale	2.10	394,865	828,269	3,248,366	Oct 11 04:35 PM
Carlyle Group Inc.	10% Owner	Oct 09 '24	Sale	2.14	924,466	1,981,223	3,643,231	Oct 11 04:30 PM
Carlyle Group Inc.	10% Owner	Oct 10 '24	Sale	2.10	394,865	828,269	3,248,366	Oct 11 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 08 '24	Sale	2.45	200,000	490,940	4,567,697	Oct 09 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 07 '24	Sale	2.51	133,643	335,698	4,767,697	Oct 09 04:30 PM
Carlyle Group Inc.	10% Owner	Oct 08 '24	Sale	2.45	200,000	490,940	4,567,697	Oct 09 04:30 PM
Carlyle Group Inc.	10% Owner	Oct 07 '24	Sale	2.51	133,643	335,698	4,767,697	Oct 09 04:30 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Oct 07 '24	Proposed Sale	2.71	4,297,229	11,645,490		Oct 07 01:10 PM
Gishen Adam	Director	Aug 19 '24	Sale	1.75	15,526	27,177	337,742	Aug 21 04:30 PM
Thiam Tidjane	Director	Aug 16 '24	Sale	1.59	30,000	47,700	158,624	Aug 20 05:54 PM
Carlyle Group Inc.	10% Owner	Jul 18 '24	Sale	1.40	35,143	49,200	4,901,340	Aug 07 04:48 PM
CRSEF Solis Holdings, L.L.C.	10% Owner	Jul 18 '24	Sale	1.40	35,143	49,200	4,901,340	Aug 07 04:30 PM

Open in Screener

QDEL

QuidelOrtho Corporation

Oct 22 • 04:00PM ET

39.65

Dollar change -0.19
Percentage change -0.48	%

Healthcare • Medical Devices • USA • NASD

QDEL QuidelOrtho Corporation daily Stock Chart

Peers: ABT TMO BDX BIO HOLX DGX LH ALC COO RMD

| Held by: IJR VTI VB VBR VXF AVUV IJS SPSM IHI SLYV

Index	-	P/E	-	EPS (ttm)	-27.79	Insider Own	13.74%	Shs Outstand	66.70M	Perf Week	-1.37%
Market Cap	2.67B	Forward P/E	13.52	EPS next Y	2.93	Insider Trans	-31.25%	Shs Float	58.00M	Perf Month	-11.38%
Income	-1859.40M	PEG	-	EPS next Q	0.27	Inst Own	84.64%	Short Float	7.19%	Perf Quarter	3.26%
Sales	2.83B	P/S	0.94	EPS this Y	-58.07%	Inst Trans	7.26%	Short Ratio	4.16	Perf Half Y	-1.86%
Book/sh	47.30	P/B	0.84	EPS next Y	69.37%	ROA	-24.40%	Short Interest	4.17M	Perf Year	-40.98%
Cash/sh	1.59	P/C	24.92	EPS next 5Y	7.20%	ROE	-45.48%	52W Range	29.74 - 75.86	Perf YTD	-46.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-33.45%	52W High	-47.73%	Beta	0.09
Dividend TTM	-	Quick Ratio	0.79	Sales past 5Y	59.83%	Gross Margin	40.45%	52W Low	33.34%	ATR (14)	1.35
Dividend Ex-Date	-	Current Ratio	1.44	EPS Y/Y TTM	-4184.55%	Oper. Margin	3.46%	RSI (14)	35.12	Volatility	3.65% 3.00%
Employees	7100	Debt/Eq	0.87	Sales Y/Y TTM	-10.37%	Profit Margin	-65.72%	Recom	2.22	Target Price	53.57
Option/Short	Yes / Yes	LT Debt/Eq	0.75	EPS Q/Q	-176.39%	Payout	-	Rel Volume	0.36	Prev Close	39.84
Sales Surprise	3.83%	EPS Surprise	69.97%	Sales Q/Q	-4.07%	Earnings	Nov 07 AMC	Avg Volume	1.00M	Price	39.65
SMA20	-6.39%	SMA50	-8.85%	SMA200	-12.84%	Trades		Volume	365,875	Change	-0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-24	Resumed	UBS	Neutral	$42 → $50
Sep-05-24	Upgrade	Craig Hallum	Hold → Buy	$40 → $57
Mar-04-24	Downgrade	UBS	Neutral → Sell	$70 → $42
Feb-14-24	Downgrade	JP Morgan	Neutral → Underweight	$66 → $37
Dec-11-23	Downgrade	Citigroup	Buy → Neutral	$95 → $72
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$90 → $125
Dec-07-22	Initiated	RBC Capital Mkts	Outperform	$125
Oct-14-22	Upgrade	UBS	Sell → Neutral	$86
Sep-19-22	Initiated	Citigroup	Neutral	$90
Jul-20-22	Initiated	UBS	Sell	$86
Jun-17-22	Resumed	JP Morgan	Neutral	$80 → $110
Feb-22-22	Upgrade	Raymond James	Outperform → Strong Buy	$155 → $130
Jan-22-21	Upgrade	Raymond James	Mkt Perform → Outperform	$250
May-12-20	Downgrade	JP Morgan	Neutral → Underweight	$120 → $158
Mar-26-20	Downgrade	Barclays	Overweight → Equal Weight	$90
Oct-23-18	Resumed	Raymond James	Strong Buy	$80
Mar-08-18	Upgrade	Raymond James	Outperform → Strong Buy
Jan-22-18	Reiterated	Barclays	Overweight	$50 → $60
Jan-04-18	Upgrade	CL King	Neutral → Buy
Sep-19-17	Upgrade	Piper Jaffray	Neutral → Overweight

Show Previous Ratings

Oct-17-24 07:00AM	QuidelOrtho to Report Third Quarter 2024 Financial Results (Business Wire)
Oct-09-24 07:00AM	QuidelOrtho Announces New R&D Executive Leader (Business Wire)
Sep-10-24 07:00AM	QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer (Business Wire)
Sep-05-24 05:25PM	Why QuidelOrtho Stock Blasted 10% Higher Today (Motley Fool) +10.26%
Aug-29-24 07:00AM	VITROS Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S. (Business Wire)
07:00AM	Loading…
Aug-19-24 07:00AM	QuidelOrtho to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-24 04:55PM	Is Jana Partners Starting an Activist Campaign Against QuidelOrtho Corporation (QDEL)? (Insider Monkey)
Jul-31-24 04:05PM	QuidelOrtho Reports Second Quarter 2024 Financial Results (Business Wire) +6.90%
Jul-23-24 07:17PM	Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600 (PR Newswire)
Jul-17-24 07:00AM	QuidelOrtho to Report Second Quarter 2024 Financial Results (Business Wire)
Jun-26-24 08:52AM	Should You Sell QuidelOrtho Corporation (QDEL)? (Insider Monkey)
Jun-25-24 06:41AM	What Made The Brown Capital Management Small Company Fund to Sell QuidelOrtho Corporation (QDEL)? (Insider Monkey)
Jun-19-24 08:27AM	QuidelOrtho Corporation (QDEL) is Excited about the New Product Launch (Insider Monkey)
05:13AM	QuidelOrtho (QDEL) Trembled on Disappointing Guidance (Insider Monkey)
Jun-07-24 11:30AM	Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report? (Zacks)
05:45AM	Loading…
Jun-04-24 05:45AM	QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - QDEL (PR Newswire)
May-30-24 06:20AM	Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDEL (PR Newswire)
May-27-24 04:28AM	QuidelOrtho (QDEL) Fell after Reporting Below Expected Results (Insider Monkey)
May-23-24 07:00AM	QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference (Business Wire)
May-17-24 01:03PM	Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights QDEL (GlobeNewswire)
May-15-24 04:05PM	QuidelOrtho Opens New Distribution Center in Pedricktown, NJ (Business Wire)
May-10-24 01:02PM	QuidelOrtho Corp Reports Mixed Q1 2024 Results Amid Strategic Shifts and Market Challenges (GuruFocus.com)
12:48PM	QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights QDEL (GlobeNewswire)
May-09-24 01:28PM	QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall (Zacks)
11:14AM	QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
04:06AM	QuidelOrtho Corp (QDEL) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ... (GuruFocus.com)
May-08-24 08:56PM	QDEL Stock Earnings: QuidelOrtho Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:25PM	QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates (Zacks)
04:05PM	QuidelOrtho Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 09:16AM	Unveiling QuidelOrtho (QDEL) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
05:45AM	Loading…
05:45AM	QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDEL (PR Newswire)
May-03-24 06:00AM	QuidelOrtho names ex-Abbott exec Brian Blaser as CEO (MedTech Dive)
May-02-24 08:00AM	QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer (Business Wire) +6.40%
May-01-24 10:01AM	Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-24 08:15PM	QDEL Investors With Large Losses Should Contact Robbins LLP for Information About Their Rights in Connection With the QuidelOrtho Corporation Lawsuit (Business Wire)
Apr-17-24 07:00AM	QuidelOrtho To Report First Quarter 2024 Financial Results (Business Wire)
Apr-12-24 11:47AM	QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing (Zacks)
Apr-10-24 07:00AM	QuidelOrtho Adds Fentanyl Test to Its Vitros Systems as a MicroTip Partnership Assay (Business Wire)
Apr-03-24 10:48AM	QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing (Zacks)
06:38AM	QuidelOrtho pulls FDA submission of 4-virus test (MedTech Dive)
Apr-02-24 09:00AM	QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue COVID-19 Test (Business Wire) -10.32%
Mar-14-24 07:23AM	QuidelOrtho to lay off employees after firing CEO (MedTech Dive)
Mar-07-24 10:44AM	QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis (Zacks)
Mar-06-24 04:35PM	QuidelOrtho Receives Health Canada Approval for Quidel Triage PLGF Test for Laboratory Use in Canada (Business Wire)
Feb-26-24 04:30PM	QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference (Business Wire)
Feb-21-24 07:30AM	QuidelOrtho Announces Changes in Executive Leadership (Business Wire) +6.20%
05:27AM	QuidelOrtho fires CEO Doug Bryant (MedTech Dive)
Feb-20-24 01:49PM	QuidelOrtho (QDEL) Stock Crashes After Posting YoY Revenue Decline, Analyst Downgrades - Hagens Berman (GlobeNewswire) +11.57%
Feb-14-24 08:34PM	QuidelOrtho (QDEL) Stock Crashes After Posting YoY Revenue Decline, Analyst Downgrades - Hagens Berman (GlobeNewswire) -32.20%
10:05AM	QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall (Zacks)
09:22AM	QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-13-24 07:30PM	QuidelOrtho (QDEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:30PM	QuidelOrtho (QDEL) Misses Q4 Earnings and Revenue Estimates (Zacks)
04:40PM	QuidelOrtho Corp (QDEL) Reports Mixed Results Amidst Respiratory Revenue Decline (GuruFocus.com)
04:05PM	QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-12-24 09:16AM	Insights Into QuidelOrtho (QDEL) Q4: Wall Street Projections for Key Metrics (Zacks)
Jan-23-24 07:00AM	QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results (Business Wire)
Dec-22-23 07:00AM	QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-23 04:05PM	QuidelOrtho Receives 510(K) Clearance for Savanna Multiplex Molecular Platform and Savanna HSV 1+2/VZV PCR Assay (Business Wire)
Dec-13-23 05:10AM	Why is QuidelOrtho (QDEL) a Good Stock to Invest in? (Insider Monkey) +7.61%
Nov-16-23 05:05PM	QuidelOrtho to Participate in the Evercore ISI Conference (Business Wire)
Nov-01-23 05:56PM	QuidelOrtho Corp (QDEL) Reports Q3 2023 Financial Results: Revenue at $744 Million (GuruFocus.com)
04:05PM	QuidelOrtho Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-17-23 03:43PM	Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times Square (PR Newswire)
Oct-12-23 07:00AM	QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023 (Business Wire) -6.17%
Sep-21-23 04:05PM	QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA (Business Wire)
07:02AM	Should You Add QuidelOrtho (QDEL) to Your Portfolio? (Insider Monkey)
Aug-28-23 04:05PM	QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire) +6.33%
Aug-08-23 04:30PM	QuidelOrtho Reports Second Quarter 2023 Financial Results (Business Wire) -7.27%
Jul-25-23 04:00PM	QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row (Business Wire)
01:12PM	QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings (Business Wire)
Jul-19-23 08:15AM	The three-year shareholder returns and company earnings persist lower as QuidelOrtho (NASDAQ:QDEL) stock falls a further 3.2% in past week (Simply Wall St.)
Jul-18-23 04:05PM	QuidelOrtho to Report Second Quarter 2023 Financial Results (Business Wire)
Jun-21-23 08:00PM	QDEL: What does Argus have to say about QDEL? (Argus Research)
Jun-12-23 11:20AM	Declining Stock and Decent Financials: Is The Market Wrong About QuidelOrtho Corporation (NASDAQ:QDEL)? (Simply Wall St.)
May-23-23 07:00AM	QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference (Business Wire)
May-04-23 07:50AM	Q1 2023 QuidelOrtho Corp Earnings Call (Thomson Reuters StreetEvents) -6.53%
May-03-23 04:05PM	QuidelOrtho Reports First Quarter 2023 Financial Results (Business Wire)
Apr-26-23 08:00PM	QDEL: Lowering target price to $74.00 (Argus Research)
Apr-13-23 04:05PM	QuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023 (Business Wire) +5.01%
Mar-28-23 11:05AM	QuidelOrtho Announces the Formation of the International QuidelOrtho Womens Leadership Network (QWLN) (Business Wire)
07:54AM	QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 36% Below Their Intrinsic Value Estimate (Simply Wall St.)
Mar-23-23 12:19PM	3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio (Zacks)
Mar-13-23 01:00PM	QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval (Zacks)
Mar-08-23 04:05PM	QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA (Business Wire)
Mar-04-23 09:08AM	17 High Growth Low PE Stocks (Insider Monkey)
08:19AM	13 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-02-23 02:01PM	QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference (Business Wire)
Feb-27-23 11:00AM	ImageMover and QuidelOrtho Partner to Simplify Test-to-Treat Process for Pharmacies (PR Newswire)
05:13AM	QuidelOrtho Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Feb-26-23 08:04AM	12 High Growth Healthcare Stocks to Buy (Insider Monkey)
Feb-18-23 07:14AM	QuidelOrtho Corporation Just Missed Revenue By 8.0%: Here's What Analysts Think Will Happen Next (Simply Wall St.)
Feb-16-23 06:18PM	QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.66%
12:07PM	QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down (Zacks)
Feb-15-23 04:05PM	QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-09-23 06:34AM	QuidelOrtho (NASDAQ:QDEL) pulls back 4.3% this week, but still delivers shareholders favorable 14% CAGR over 5 years (Simply Wall St.)
Jan-24-23 03:25PM	Top Healthcare Stocks (Investopedia)
Jan-06-23 04:05PM	QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022 (Business Wire) -5.08%
Jan-03-23 09:53AM	Is QuidelOrtho Corporation's (NASDAQ:QDEL) Latest Stock Performance A Reflection Of Its Financial Health? (Simply Wall St.)
Dec-28-22 07:00AM	QuidelOrtho to Present at the J.P. Morgan Healthcare Conference (Business Wire)

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carlyle Group Inc.	10% Owner	Aug 09 '24	Sale	41.53	74,134	3,078,980	8,260,183	Aug 13 04:30 PM
Carlyle Group Inc.	10% Owner	Aug 08 '24	Sale	41.07	106,705	4,382,446	8,334,317	Aug 09 04:15 PM
Carlyle Group Inc.	10% Owner	Aug 07 '24	Sale	39.94	78,180	3,122,840	8,441,022	Aug 09 04:15 PM
Carlyle Group Inc.	10% Owner	Aug 05 '24	Sale	40.37	118,172	4,770,960	8,606,174	Aug 07 04:30 PM
Carlyle Group Inc.	10% Owner	Aug 06 '24	Sale	40.23	86,972	3,499,160	8,519,202	Aug 07 04:30 PM
Carlyle Partners VI Cayman Hol	10% Owner	Aug 06 '24	Proposed Sale	42.01	246,775	10,367,018		Aug 05 08:28 PM
Carlyle Group Inc.	10% Owner	Aug 01 '24	Sale	41.52	234,935	9,753,465	8,893,813	Aug 05 04:30 PM
Carlyle Group Inc.	10% Owner	Aug 02 '24	Sale	42.10	169,467	7,134,818	8,724,346	Aug 05 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 31 '24	Sale	39.11	164,877	6,447,760	9,128,748	Aug 01 05:01 PM
Carlyle Group Inc.	10% Owner	Jul 30 '24	Sale	39.74	150,590	5,985,089	9,293,625	Aug 01 05:01 PM
Carlyle Group Inc.	10% Owner	Jul 29 '24	Sale	38.85	158,090	6,142,230	9,444,215	Jul 30 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 26 '24	Sale	39.05	103,926	4,058,307	9,602,305	Jul 30 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 25 '24	Sale	38.58	406,809	15,696,721	9,706,231	Jul 26 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 24 '24	Sale	38.97	214,732	8,367,685	10,113,040	Jul 26 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 22 '24	Sale	35.31	135,241	4,775,665	10,427,317	Jul 24 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 23 '24	Sale	36.52	99,545	3,635,490	10,327,772	Jul 24 04:30 PM
WIDDER KENNETH J	Director	Jul 19 '24	Option Exercise	27.91	3,333	93,024	28,472	Jul 23 06:43 PM
Carlyle Group Inc.	10% Owner	Jul 18 '24	Sale	34.13	101,870	3,476,615	10,628,194	Jul 22 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 19 '24	Sale	34.12	65,636	2,239,738	10,562,558	Jul 22 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 16 '24	Sale	33.16	94,861	3,145,151	10,799,701	Jul 18 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 17 '24	Sale	34.81	69,637	2,423,818	10,730,064	Jul 18 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 15 '24	Sale	31.70	93,187	2,954,302	10,894,562	Jul 16 08:17 PM
Carlyle Group Inc.	10% Owner	Jul 12 '24	Sale	32.35	57,253	1,852,189	10,987,749	Jul 16 08:17 PM
Carlyle Group Inc.	10% Owner	Jul 11 '24	Sale	31.37	96,578	3,030,060	11,045,002	Jul 12 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 10 '24	Sale	30.09	24,390	733,971	11,141,580	Jul 12 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 08 '24	Sale	30.39	59,973	1,822,715	11,189,751	Jul 10 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 09 '24	Sale	30.07	23,781	715,109	11,165,970	Jul 10 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 03 '24	Sale	30.87	52,724	1,627,441	11,300,463	Jul 08 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 05 '24	Sale	31.15	50,739	1,580,626	11,249,724	Jul 08 04:30 PM
Carlyle Group Inc.	10% Owner	Jul 02 '24	Sale	31.36	86,454	2,711,095	11,353,187	Jul 03 01:15 PM
Carlyle Group Inc.	10% Owner	Jul 01 '24	Sale	32.21	81,110	2,612,556	11,439,641	Jul 03 01:15 PM
Carlyle Group Inc.	10% Owner	Jun 28 '24	Sale	33.05	49,937	1,650,252	11,520,751	Jul 01 04:30 PM
Carlyle Group Inc.	10% Owner	Jun 27 '24	Sale	33.51	46,380	1,554,398	11,570,688	Jul 01 04:30 PM
Carlyle Group Inc.	10% Owner	Jun 26 '24	Sale	33.19	81,482	2,704,541	11,617,068	Jun 27 04:30 PM
Carlyle Group Inc.	10% Owner	Jun 25 '24	Sale	33.01	67,472	2,227,342	11,698,550	Jun 27 04:30 PM
Carlyle Group Inc.	10% Owner	Jun 24 '24	Sale	34.34	73,713	2,531,371	11,766,022	Jun 25 04:56 PM
Carlyle Group Inc.	10% Owner	Jun 21 '24	Sale	35.07	68,580	2,404,799	11,839,735	Jun 25 04:56 PM
Carlyle Group Inc.	10% Owner	Jun 20 '24	Sale	34.89	67,207	2,344,618	11,908,315	Jun 21 04:30 PM
Carlyle Group Inc.	10% Owner	Jun 18 '24	Sale	35.96	48,541	1,745,606	11,975,522	Jun 21 04:30 PM
Carlyle Group Inc.	10% Owner	Jun 14 '24	Sale	36.19	127,981	4,631,842	12,123,705	Jun 18 05:46 PM
Carlyle Group Inc.	10% Owner	Jun 17 '24	Sale	35.99	99,642	3,586,163	12,024,063	Jun 18 05:46 PM
Carlyle Group Inc.	10% Owner	Jun 13 '24	Sale	37.67	144,234	5,433,190	12,251,686	Jun 14 05:02 PM
Carlyle Group Inc.	10% Owner	Jun 12 '24	Sale	40.23	64,263	2,585,270	12,395,920	Jun 14 05:02 PM
BUECHLER KENNETH F	Director	Apr 12 '24	Option Exercise	21.07	9,041	190,494	83,679	Apr 16 06:18 PM
Busky Joseph M	Chief Financial Officer	Feb 23 '24	Buy	46.35	2,150	99,663	2,150	Feb 26 06:48 PM

Open in Screener

JSPR

Jasper Therapeutics Inc

Oct 22 • 04:00PM ET

20.08

Dollar change +0.18
Percentage change 0.90	%

Healthcare • Biotechnology • USA • NASD

JSPR Jasper Therapeutics Inc daily Stock Chart

Peers: CRSP NTLA EDIT BEAM ADAP RCKT BLUE CLLS SGMO AFMD

| Held by: VTI IWM VXF IWO VTWO IWC FESM AVSC VFMO CANC

Index	RUT	P/E	-	EPS (ttm)	-5.10	Insider Own	23.35%	Shs Outstand	15.11M	Perf Week	9.85%
Market Cap	303.41M	Forward P/E	-	EPS next Y	-4.15	Insider Trans	-0.05%	Shs Float	11.58M	Perf Month	-6.76%
Income	-62.44M	PEG	-	EPS next Q	-1.07	Inst Own	77.44%	Short Float	12.90%	Perf Quarter	-3.23%
Sales	0.00M	P/S	-	EPS this Y	32.51%	Inst Trans	21.27%	Short Ratio	6.08	Perf Half Y	-9.18%
Book/sh	6.64	P/B	3.02	EPS next Y	0.52%	ROA	-52.45%	Short Interest	1.49M	Perf Year	200.06%
Cash/sh	7.07	P/C	2.84	EPS next 5Y	-	ROE	-59.32%	52W Range	4.00 - 31.01	Perf YTD	154.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-61.45%	52W High	-35.25%	Beta	2.22
Dividend TTM	-	Quick Ratio	10.79	Sales past 5Y	0.00%	Gross Margin	-	52W Low	402.00%	ATR (14)	1.64
Dividend Ex-Date	-	Current Ratio	10.79	EPS Y/Y TTM	48.65%	Oper. Margin	0.00%	RSI (14)	58.96	Volatility	8.22% 9.46%
Employees	45	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.09	Target Price	71.62
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	33.91%	Payout	-	Rel Volume	1.00	Prev Close	19.90
Sales Surprise	-	EPS Surprise	10.89%	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	245.98K	Price	20.08
SMA20	14.44%	SMA50	4.54%	SMA200	-2.46%	Trades		Volume	353,201	Change	0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-24	Initiated	JMP Securities	Mkt Outperform	$70
Jul-08-24	Initiated	BTIG Research	Buy	$90
Jun-27-24	Initiated	Stifel	Buy	$86
May-06-24	Initiated	H.C. Wainwright	Buy	$65
Apr-03-24	Initiated	Evercore ISI	Outperform	$65
Mar-28-24	Initiated	RBC Capital Mkts	Outperform	$70
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight	$7
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-08-21	Initiated	Credit Suisse	Outperform	$15
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform	$19
Oct-13-21	Initiated	Oppenheimer	Outperform	$21

Show Previous Ratings

Today 08:00AM	Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria (GlobeNewswire)
Oct-14-24 07:00AM	Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +10.46%
Sep-10-24 07:30AM	Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma (GlobeNewswire) +5.13%
Sep-04-24 04:30PM	Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 07:00AM	Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.40%
08:00AM	Loading…
Jun-19-24 08:00AM	Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors (GlobeNewswire)
Jun-17-24 04:30PM	Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit (GlobeNewswire)
Jun-14-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress (GlobeNewswire)
May-30-24 06:05PM	Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 (GlobeNewswire) +7.72%
May-29-24 04:30PM	Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-13-24 08:00AM	Jasper Therapeutics Announces Briquilimab Development Program in Asthma (GlobeNewswire)
May-07-24 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire) -6.94%
12:00PM	Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know (Zacks)
04:30PM	Loading…
Apr-02-24 04:30PM	Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
Mar-22-24 08:50AM	Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-21-24 04:30PM	Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) +8.01%
Mar-19-24 08:00AM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +5.55%
Mar-15-24 08:00AM	New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
Mar-14-24 12:00PM	Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know (Zacks) -9.11%
Mar-06-24 12:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +8.21%
08:50AM	Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going (Zacks)
Mar-04-24 07:30AM	Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-26-24 04:30PM	Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-23-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-19-24 08:50AM	Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength (Zacks)
Feb-07-24 08:00AM	Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference (GlobeNewswire) +18.00%
Feb-06-24 08:59AM	Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock (GlobeNewswire) +14.52%
Feb-05-24 08:00AM	Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire) +7.65%
08:00AM	Loading…
Feb-02-24 08:00AM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-24 12:14PM	Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why (Zacks)
Jan-05-24 08:30AM	Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones (GlobeNewswire)
Jan-02-24 08:00AM	Jasper Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -13.74%
Dec-18-23 04:30PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.11%
Dec-10-23 11:00AM	Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 (GlobeNewswire)
Nov-30-23 08:00AM	Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-09-23 09:48AM	Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -8.08%
08:00AM	Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors (GlobeNewswire)
Oct-09-23 08:30AM	Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023 (GlobeNewswire) +16.25%
08:00AM	Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Sep-25-23 08:00AM	Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer (GlobeNewswire) -8.97%
Sep-21-23 08:00AM	Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium (GlobeNewswire)
Sep-15-23 08:00AM	Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference (GlobeNewswire) +10.96%
Aug-11-23 04:05PM	Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-04-23 04:51PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 08:00AM	Jasper Therapeutics Strengthens Management Team with Key Appointments (GlobeNewswire)
Jun-22-23 08:00AM	Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome (GlobeNewswire)
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
Jun-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer (GlobeNewswire) +6.17%
May-12-23 04:05PM	Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +5.37%
May-10-23 08:00AM	Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board (GlobeNewswire)
Apr-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources (GlobeNewswire)
Apr-10-23 04:05PM	Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations (GlobeNewswire)
Mar-31-23 08:00AM	Jasper Therapeutics to Present at Cantor Fitzgeralds The Future of Oncology Virtual Symposium (GlobeNewswire)
Mar-23-23 08:00AM	Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer (GlobeNewswire)
Mar-09-23 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -7.00%
Mar-08-23 04:05PM	Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-17-23 08:20AM	Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors (GlobeNewswire)
08:10AM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
08:00AM	Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
Feb-16-23 04:05PM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients (GlobeNewswire)
Feb-03-23 04:05PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.43%
Jan-30-23 08:00AM	Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023 (GlobeNewswire)
Jan-27-23 01:10PM	Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jan-25-23 08:00AM	Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock (GlobeNewswire) +9.47%
Jan-24-23 04:25PM	Jasper Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.59%
Jan-13-23 08:00AM	Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire) +7.88%
Jan-10-23 08:00AM	Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases (GlobeNewswire)
Jan-04-23 08:00AM	Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant (GlobeNewswire) -21.90%
Jan-03-23 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia (GlobeNewswire) +467.41%
Nov-10-22 04:05PM	Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Sep-26-22 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting (GlobeNewswire)
Sep-23-22 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -13.49%
Sep-15-22 08:00AM	Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant (GlobeNewswire)
Aug-12-22 04:05PM	Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) -7.08%
Jun-23-22 04:05PM	Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +17.34% +15.27%
Jun-20-22 10:59AM	Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-07-22 08:00AM	Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference (GlobeNewswire) -5.70%
Jun-06-22 08:00AM	Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 (GlobeNewswire)
May-27-22 08:00AM	After a record-breaking decade, biotech is discovering what hard times feel like (American City Business Journals)
May-17-22 08:00AM	Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
May-12-22 04:05PM	Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-28-22 08:00AM	Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting (GlobeNewswire)
Apr-26-22 04:05PM	Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation (GlobeNewswire)
Apr-22-22 08:00AM	Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies (GlobeNewswire)
Mar-31-22 08:00AM	Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting (GlobeNewswire) +5.97%
Mar-25-22 07:30PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-22 08:30AM	Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team (GlobeNewswire)
Mar-18-22 04:05PM	Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-10-22 08:00AM	Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -7.96%
Feb-28-22 08:00AM	Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer (GlobeNewswire)
Feb-24-22 05:19PM	Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-02-22 01:38PM	Grace Capital Buys Vanguard Consumer Discretionary ETF, Tesla Inc, Jasper Therapeutics Inc, ... (GuruFocus.com) -12.07%
Dec-08-21 11:15AM	Billionaire Ken Griffin Goes Big on These 3 Strong Buy Stocks (TipRanks) +6.00%
08:30AM	Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-20-21 08:21AM	Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth (Simply Wall St.)

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mahal Jeetinder Singh	Chief Operating Officer	Sep 12 '24	Option Exercise	7.10	900	6,390	25,909	Sep 12 05:19 PM
Mahal Jeetinder Singh	Chief Operating Officer	Sep 12 '24	Sale	21.23	900	19,104	25,009	Sep 12 05:19 PM
Jeetinder Singh Mahal	Executive Officer	Sep 12 '24	Proposed Sale	20.66	900	18,590		Sep 12 05:18 PM
Mahal Jeetinder Singh	Chief Operating Officer	Jun 12 '24	Option Exercise	7.10	900	6,390	25,909	Jun 12 09:40 PM
Mahal Jeetinder Singh	Chief Operating Officer	Jun 12 '24	Sale	24.16	900	21,740	25,009	Jun 12 09:40 PM
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Option Exercise	7.10	900	6,390	25,909	Mar 12 09:33 PM
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Sale	26.44	900	23,792	25,009	Mar 12 09:33 PM
Carlyle Group Inc.	Former 10% Owner	Feb 08 '24	Buy	12.95	190,000	2,460,500	1,066,189	Feb 12 06:23 PM
Velan Capital Investment Manag	10% Owner	Feb 08 '24	Buy	12.95	350,000	4,532,500	1,188,500	Feb 09 08:40 PM
WIGGANS THOMAS G	Director	Nov 28 '23	Buy	0.65	10,000	6,486	50,000	Nov 30 04:05 PM
WIGGANS THOMAS G	Director	Nov 21 '23	Buy	0.64	10,000	6,383	40,000	Nov 22 04:06 PM
WIGGANS THOMAS G	Director	Nov 20 '23	Buy	0.63	10,000	6,309	30,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 17 '23	Buy	0.60	10,000	5,966	20,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 16 '23	Buy	0.60	10,000	5,965	10,000	Nov 20 08:14 PM

Dollar change -1.21
Percentage change -1.20	%

MKSI MKS Instruments, Inc. daily Stock Chart

Peers: AMAT LRCX KLAC TER COHR UCTT AEIS IPGP ON NOVA

| Held by: VTI IJH VB VBR VXF SOXX VGT MDY SOXL SCHA

Index	-	P/E	779.70	EPS (ttm)	0.13	Insider Own	0.55%	Shs Outstand	67.29M	Perf Week	-3.93%
Market Cap	6.72B	Forward P/E	13.34	EPS next Y	7.49	Insider Trans	-0.76%	Shs Float	66.92M	Perf Month	-8.74%
Income	9.00M	PEG	29.81	EPS next Q	1.45	Inst Own	101.70%	Short Float	2.77%	Perf Quarter	-19.06%
Sales	3.58B	P/S	1.88	EPS this Y	27.21%	Inst Trans	-1.69%	Short Ratio	2.04	Perf Half Y	-11.27%
Book/sh	33.18	P/B	3.01	EPS next Y	32.88%	ROA	0.10%	Short Interest	1.85M	Perf Year	34.90%
Cash/sh	12.65	P/C	7.90	EPS next 5Y	26.16%	ROE	0.38%	52W Range	63.44 - 147.40	Perf YTD	-2.91%
Dividend Est.	0.88 (0.88%)	P/FCF	17.19	EPS past 5Y	-	ROI	0.12%	52W High	-32.24%	Beta	1.61
Dividend TTM	0.88 (0.88%)	Quick Ratio	2.31	Sales past 5Y	12.63%	Gross Margin	39.30%	52W Low	57.44%	ATR (14)	3.83
Dividend Ex-Date	Aug 26, 2024	Current Ratio	3.58	EPS Y/Y TTM	100.50%	Oper. Margin	13.18%	RSI (14)	37.72	Volatility	2.41% 3.30%
Employees	10200	Debt/Eq	2.29	Sales Y/Y TTM	-6.67%	Profit Margin	0.25%	Recom	1.71	Target Price	136.67
Option/Short	Yes / Yes	LT Debt/Eq	2.25	EPS Q/Q	101.29%	Payout	-	Rel Volume	0.96	Prev Close	101.09
Sales Surprise	2.38%	EPS Surprise	46.17%	Sales Q/Q	-11.57%	Earnings	Nov 06 AMC	Avg Volume	907.43K	Price	99.88
SMA20	-6.10%	SMA50	-9.57%	SMA200	-16.55%	Trades		Volume	897,994	Change	-1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-24	Downgrade	Citigroup	Buy → Neutral	$145 → $120
Sep-10-24	Initiated	Cantor Fitzgerald	Overweight	$140
Sep-03-24	Initiated	Goldman	Neutral	$129
Aug-05-24	Initiated	Morgan Stanley	Overweight	$155
Jul-10-24	Initiated	BofA Securities	Buy	$160
Jun-20-24	Resumed	Deutsche Bank	Hold	$140
Mar-01-23	Upgrade	The Benchmark Company	Hold → Buy	$125
Dec-20-22	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$100
Nov-04-22	Downgrade	The Benchmark Company	Buy → Hold
Feb-23-22	Initiated	Loop Capital	Buy	$200
Jan-26-22	Initiated	KeyBanc Capital Markets	Sector Weight
Dec-27-21	Reiterated	Needham	Buy	$215
Dec-13-21	Upgrade	Citigroup	Neutral → Buy	$190
Oct-29-21	Resumed	Rosenblatt	Buy
Aug-20-21	Resumed	Citigroup	Neutral	$160
Jul-06-21	Resumed	Deutsche Bank	Buy	$225
Dec-11-20	Reiterated	Cowen	Outperform	$150 → $178
Sep-11-20	Initiated	Berenberg	Buy
Jul-28-20	Reiterated	Needham	Buy	$125 → $135
Jul-22-20	Initiated	Rosenblatt	Buy	$162

Show Previous Ratings

Oct-18-24 10:53AM	MKS Instruments (MKSI) Failed to Meet Investors Expectations (Insider Monkey)
09:40AM	Here's Why MKS Instruments (MKSI) is a Strong Value Stock (Zacks)
Oct-14-24 08:00AM	MKS Instruments Announces Third Quarter 2024 Earnings Conference Call (GlobeNewswire)
Sep-25-24 09:40AM	Why MKS Instruments (MKSI) is a Top Value Stock for the Long-Term (Zacks)
Sep-10-24 09:00AM	MKS Instruments CEO to be Honored as Pinnacle Award Winner by the Asian American Business Development Center (GlobeNewswire)
09:40AM	Loading…
Sep-09-24 09:40AM	Here's Why MKS Instruments (MKSI) is a Strong Value Stock (Zacks)
Sep-06-24 11:31AM	Why Is MKS Instruments (MKSI) Down 1.3% Since Last Earnings Report? (Zacks)
Sep-04-24 09:50AM	Why MKS Instruments (MKSI) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-21-24 09:00AM	MKS Instruments to Participate in Citi's 2024 Global TMT Conference (GlobeNewswire)
Aug-13-24 09:00AM	Ram Mayampurath to Join MKS Instruments as Chief Financial Officer (GlobeNewswire) +5.31%
Aug-08-24 11:51PM	Q2 2024 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents) +6.23%
08:49AM	MKS Instruments (MKSI) Q2 Earnings Top Estimates, Revenues Down (Zacks)
Aug-07-24 07:50PM	MKS Instruments (MKSI) Q2 Earnings and Revenues Surpass Estimates (Zacks)
06:55PM	MKS Instruments: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	MKS Instruments Reports Second Quarter 2024 Financial Results (GlobeNewswire)
09:40AM	Loading…
Aug-06-24 09:40AM	Why MKS Instruments (MKSI) is a Top Value Stock for the Long-Term (Zacks)
09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Aug-05-24 09:45AM	Here's Why MKS Instruments (MKSI) is a Strong Growth Stock (Zacks)
Aug-01-24 01:37PM	MKS Instruments (MKSI) Surges 5.6%: Is This an Indication of Further Gains? (Zacks) -8.86%
12:45PM	Here is Why Growth Investors Should Buy MKS Instruments (MKSI) Now (Zacks)
Jul-31-24 10:01AM	MKS Instruments (MKSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks) +5.57%
Jul-29-24 09:00AM	MKS Instruments Releases 2024 Environmental, Social, Governance Report (GlobeNewswire)
Jul-23-24 12:10PM	Will MKS Instruments (MKSI) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:00AM	MKS Instruments Completes Repricing and Makes a $110 Million Voluntary Prepayment on its Secured Term Loan B (GlobeNewswire)
Jul-19-24 09:45AM	Why MKS Instruments (MKSI) is a Top Growth Stock for the Long-Term (Zacks)
Jul-16-24 12:45PM	Looking for a Growth Stock? 3 Reasons Why MKS Instruments (MKSI) is a Solid Choice (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why MKS Instruments (MKSI) is a Great Choice (Zacks)
Jul-15-24 08:00AM	MKS Instruments Announces Second Quarter 2024 Earnings Conference Call (GlobeNewswire)
Jun-19-24 09:50AM	Why MKS Instruments (MKSI) is a Top Momentum Stock for the Long-Term (Zacks)
Jun-18-24 09:00AM	MKS Instruments Named in U.S. News & World Report's 2024-2025 Best Companies to Work For (GlobeNewswire)
02:18AM	Loading…
Jun-14-24 02:18AM	MKS Instruments expands to Malaysia with new Penang plant, supporting chip production (DigiTimes)
Jun-10-24 09:00AM	MKS Instruments Set to Build a Super Center Factory in Malaysia (GlobeNewswire)
Jun-07-24 11:30AM	MKS Instruments (MKSI) Up 1.4% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-06-24 03:11PM	AI Needs More Chip Factories. These Stocks Should Benefit. (Barrons.com)
May-23-24 08:00AM	MKS Instruments to Participate in BofA Securities Global Technology Conference (GlobeNewswire)
May-16-24 04:57PM	MKS Instruments Closes $1.4 Billion Debt Offering (MT Newswires)
04:15PM	MKS Instruments Announces Closing of Private Offering of $1.4 Billion of 1.25% Convertible Senior Notes, Including Full Exercise of Option to Purchase $200 Million of Additional Notes (GlobeNewswire)
May-14-24 09:00AM	Sector Update: Tech Stocks Mixed Premarket Tuesday (MT Newswires)
04:59AM	MKS Instruments Prices Upsized $1.2 Billion Private Senior Notes Offering (MT Newswires)
May-13-24 11:01PM	MKS Instruments Announces Pricing of Upsized Private Offering of $1.2 Billion of 1.25% Convertible Senior Notes (GlobeNewswire) -9.03%
02:25PM	Tap Into Trends: 3 Thematic ETFs to Capture the Market's Pulse (InvestorPlace)
09:49AM	MKS Instruments Plans to Offer $1 Billion in Private Placement of Convertible Senior Notes Due 2030 (MT Newswires)
06:37AM	MKS Instruments Announces Proposed Private Offering of $1.0 Billion of Convertible Senior Notes (GlobeNewswire)
May-10-24 12:30PM	MKS Instruments Inc (MKSI) Exceeds Q1 Earnings Expectations, Surpassing Analyst Forecasts (GuruFocus.com)
10:35AM	MKS Instruments, Inc. (NASDAQ:MKSI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 10:40PM	Q1 2024 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents)
10:59AM	MKS Instruments (MKSI) Q1 Earnings Top Estimates, Revenues Up (Zacks)
May-08-24 06:15PM	MKS Instruments (MKSI) Q1 Earnings and Revenues Beat Estimates (Zacks)
05:32PM	MKS Instruments Q1 Non-GAAP Earnings, Revenue Increase; Q2 Guidance Set -- Shares Rise After Hours (MT Newswires)
05:14PM	MKS Instruments: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	MKS Instruments Reports First Quarter 2024 Financial Results (GlobeNewswire)
09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
May-06-24 09:00AM	MKS Receives Samsung Electro-Mechanics (SEMCO) Supplier Excellence Award to Demonstrate Global Competitiveness (GlobeNewswire)
May-04-24 07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
Apr-15-24 08:00AM	MKS Instruments Announces First Quarter 2024 Earnings Conference Call (GlobeNewswire)
Mar-08-24 11:30AM	Why Is MKS Instruments (MKSI) Up 16.9% Since Last Earnings Report? (Zacks)
Mar-04-24 01:00PM	Insider Sell: EVP, GC & Secretary Kathleen Burke Sells 7,411 Shares of MKS Instruments Inc ... (GuruFocus.com)
Feb-29-24 01:57AM	16 Best Future Stocks For The Long Term (Insider Monkey)
Feb-28-24 04:00PM	MKS Instruments Receives 2023 Outstanding Service Award from MFLEX (GlobeNewswire)
Feb-26-24 01:00PM	EVP, CFO & Treasurer Seth Bagshaw Sells 32,865 Shares of MKS Instruments Inc (GuruFocus.com)
Feb-09-24 09:01AM	MKS Instruments, Inc. (NASDAQ:MKSI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-08-24 09:57PM	Q4 2023 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents) +5.62%
10:30AM	MKS Instruments (MKSI) Q4 Earnings Top Estimates, Revenues Up (Zacks)
Feb-07-24 05:12PM	MKS Instruments: Q4 Earnings Snapshot (Associated Press Finance)
04:57PM	MKS Instruments Inc (MKSI) Exceeds Q4 Revenue Expectations Despite Net Loss (GuruFocus.com)
04:30PM	MKS Instruments Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-06-24 09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Jan-30-24 09:00AM	MKS Instruments Recognized by TSMC for Outstanding Production Support (GlobeNewswire)
Jan-25-24 09:00AM	MKS Instruments Selected as a 2024 Campus Forward Award Winner by RippleMatch (GlobeNewswire)
Jan-24-24 04:30PM	MKS Instruments Showcases Customer-Focused Photonics Innovations at SPIE's Photonics West 2024 (GlobeNewswire)
Jan-23-24 08:00AM	MKS Instruments Announces Fourth Quarter and Full Year 2023 Earnings Conference Call (GlobeNewswire)
Jan-22-24 04:10PM	MKS Instruments Completes Refinancing of Secured Term Loan A (GlobeNewswire)
Jan-08-24 09:00AM	MKS Instruments to Participate in Needham's 26th Annual Growth Conference (GlobeNewswire)
Dec-20-23 09:00AM	MKS Instruments Commits to Reduce Carbon Emissions (GlobeNewswire)
Dec-07-23 09:00AM	MKS Instruments Named One of America's Most Responsible Companies (GlobeNewswire)
Dec-04-23 07:00AM	Seth H. Bagshaw to Retire as Chief Financial Officer of MKS Instruments (GlobeNewswire)
Dec-01-23 11:31AM	Why Is MKS Instruments (MKSI) Up 24.8% Since Last Earnings Report? (Zacks)
05:40AM	Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now (Motley Fool)
Nov-23-23 05:08AM	MKS Instruments Inc's Dividend Analysis (GuruFocus.com)
Nov-07-23 09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Nov-03-23 03:32PM	MKS Instruments, Inc. (NASDAQ:MKSI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-01-23 06:17PM	MKS Instruments: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	MKS Instruments Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-20-23 09:00AM	MKS Instruments Announces Third Quarter 2023 Earnings Conference Call (GlobeNewswire)
Oct-18-23 05:49AM	Should You Hold MKS Instruments (MKSI)? (Insider Monkey)
Oct-10-23 09:00AM	MKS Instruments Releases Third Annual Environmental, Social, Governance Report (GlobeNewswire)
Oct-06-23 12:00PM	MKS Instruments (MKSI) Upgraded to Buy: Here's Why (Zacks)
Oct-03-23 04:30PM	MKS Instruments Completes Repricing of Secured Term Loan B (GlobeNewswire)
Sep-28-23 09:00AM	MKS Instruments Recognized as a 2024 Best Company to Work For (GlobeNewswire)
Sep-08-23 08:58AM	Zacks Industry Outlook Highlights Axcelis, MKS Instruments and Kulicke and Soffa Industries (Zacks)
Sep-07-23 12:18PM	3 Electronics Stocks to Watch From a Prospering Industry (Zacks)
Sep-01-23 11:31AM	Why Is MKS Instruments (MKSI) Down 1.2% Since Last Earnings Report? (Zacks)
Aug-28-23 09:00AM	MKS Instruments to Participate in Citis 2023 Global Technology Conference (GlobeNewswire)
Aug-13-23 09:14AM	Further weakness as MKS Instruments (NASDAQ:MKSI) drops 6.2% this week, taking three-year losses to 23% (Simply Wall St.)
Aug-08-23 09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Aug-03-23 10:26PM	Q2 2023 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents)
11:26AM	MKS Instruments (MKSI) Q2 Earnings Top Estimates, Revenues Up (Zacks)
Aug-02-23 07:35PM	MKS Instruments (MKSI) Beats Q2 Earnings and Revenue Estimates (Zacks)
06:32PM	MKS Instruments: Q2 Earnings Snapshot (AP Finance)
04:30PM	MKS Instruments Reports Second Quarter 2023 Financial Results (GlobeNewswire)

MKS Instruments, Inc. provides instruments, systems, subsystems and process control solutions to measure, control, power, monitor, and analyze parameters of manufacturing processes to improve process performance and productivity for its customers. It operates through the following segments: Vacuum & Analysis, Light & Motion and Equipment & Solutions. The Vacuum & Analysis segment comprises pressure measurement and control, flow measurement and control, gas and vapor delivery, gas composition analysis, residual gas analysis, leak detection, control technology, ozone generation and delivery, RF & DC power, reactive gas generation and vacuum technology components. The Light & Motion segment includes lasers, photonics, sub-micron positioning, vibration control, and optics instruments. The Equipment & Solutions segment provides laser-based manufacturing systems solutions for the micro-machining industry that enable customers to optimize production. The company was founded in 1961 and is headquartered in Andover, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moloney Jacqueline F	Director	Oct 01 '24	Sale	108.90	250	27,225	10,283	Oct 02 02:16 PM
Moloney Jacqueline F	Director	Oct 01 '24	Proposed Sale	108.90	250	27,225		Oct 01 11:44 AM
Mora Elizabeth	Director	Sep 03 '24	Sale	115.97	275	31,892	17,934	Sep 04 01:28 PM
Mora Elizabeth	Director	Sep 03 '24	Proposed Sale	115.97	275	31,892		Sep 03 09:47 AM
Williams John Edward	EVP & GM, PSD	Aug 16 '24	Sale	118.71	1,800	213,678	13	Aug 19 11:59 AM
Williams John Edward	Officer	Aug 16 '24	Proposed Sale	118.71	1,800	213,678		Aug 16 01:00 PM
Moloney Jacqueline F	Director	Aug 01 '24	Sale	123.46	250	30,865	10,533	Aug 02 12:13 PM
Moloney Jacqueline F	Director	Aug 01 '24	Proposed Sale	123.46	250	30,865		Aug 01 02:56 PM
Mora Elizabeth	Director	Jun 03 '24	Sale	129.41	275	35,588	18,209	Jun 04 01:45 PM
Mora Elizabeth	Director	Apr 01 '24	Sale	133.00	250	33,250	16,862	Apr 02 11:36 AM
Moloney Jacqueline F	Director	Mar 01 '24	Sale	122.89	250	30,722	9,161	Mar 04 11:43 AM
Burke Kathleen Flaherty	EVP, GC & Secretary	Mar 01 '24	Sale	122.89	7,411	910,738	42,999	Mar 04 11:39 AM
BAGSHAW SETH H	EVP, CFO & Treasurer	Feb 22 '24	Sale	123.28	32,865	4,051,629	1	Feb 26 11:51 AM
Moloney Jacqueline F	Director	Feb 16 '24	Sale	124.10	1,917	237,933	9,411	Feb 20 03:21 PM
COLELLA GERARD G	Director	Feb 09 '24	Sale	120.00	10,000	1,200,003	68,017	Feb 12 12:21 PM
COLELLA GERARD G	Director	Jan 22 '24	Sale	110.00	10,000	1,100,004	78,017	Jan 23 01:45 PM
Mora Elizabeth	Director	Jan 02 '24	Sale	100.90	250	25,225	17,112	Jan 03 01:54 PM
Moloney Jacqueline F	Director	Dec 01 '23	Sale	82.23	250	20,558	11,328	Dec 04 10:17 AM
Henry David Philip	EVP, Operations & Corp Mktg	Nov 07 '23	Buy	68.34	2,500	170,862	11,073	Nov 08 11:40 AM

CSLR

Complete Solaria Inc.

QDEL

QuidelOrtho Corporation

JSPR

Jasper Therapeutics Inc

MKSI

MKS Instruments, Inc.

Upgrade your FINVIZ experience